Person:
KUTLUĞ AĞAÇKIRAN, SEDA

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

KUTLUĞ AĞAÇKIRAN

First Name

SEDA

Name

Filters

20232
Reset filters

Settings

Author: ALİBAZ ÖNER, FATMA × Subject: Clinical Medicine (MED) ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Earlier and more aggressive treatment with biologics may prevent relapses and further new organ involvement in Behçet's disease
    (2023-03-01) BOZKURT, TUĞÇE; KARABACAK, MURAT; KUTLUĞ AĞAÇKIRAN, SEDA; DİRESKENELİ, RAFİ HANER; ALİBAZ ÖNER, FATMA; BOZKURT T., KARABACAK M., Karatas H., KUTLUĞ AĞAÇKIRAN S., Ergun T., DİRESKENELİ R. H., ALİBAZ ÖNER F.
    Objective: Immunosuppressives (IS) are the choice of treatment for major organ involvement in Behçet\"s disease (BD). In this study, we aimed to investigate the relapse rate and new major organ development in BD under ISs during long-term follow-up. Methods: The files of 1114 BD patients followed in Marmara University Behçet\"s Clinic were analyzed retrospectively. Patients with a follow-up less than 6 months were excluded. Conventional IS and biologic treatment courses were compared. ‘Events under IS’ were defined as a relapse of the same organ and/or new major organ development in patients receiving ISs. Results: Among 806 patients included in the final analysis (male: 56%, age at diagnosis: 29 (23–35) years, median follow-up time: 68 (33–106) months). Major organ involvement was present in 232 (50.5%) patients at diagnosis, and 227 (49.5%) developed new major organ involvement during follow-up. Major organ involvement developed earlier in males (p = 0.012) and in patients with a first-degree relative history of BD (p = 0.066). ISs were given mostly for major organ involvement (86.8%, n = 440). Overall, 36% of the patients had a relapse or new major organ involvement under ISs (relapse: 30.9%, new major organ involvement: 11.6%.) ‘Events under IS’ (35.5% vs 20.8%, p = 0.004), and relapses (29.3% vs 13.9%, p = 0.001) were more common with conventional ISs compared to biologics. Conclusion: Any major event under ISs was less common with biologics compared to conventional ISs in patients with BD. These results suggest that earlier and more aggressive treatment may be an option in BD patients who had the highest risk for severe disease course.
  • Thumbnail Image
    PublicationOpen Access
    Re: Risk of hbv reactivation in hbsag negative and antihbc igg positive patients receiving biologic therapy
    (2023-03-01) KANİ, HALUK TARIK; KARABACAK, MURAT; CÖMERT ÖZER, ELİF; ABACAR, KEREM YİĞİT; KUTLUĞ AĞAÇKIRAN, SEDA; SEVİK, GİZEM; ALİBAZ ÖNER, FATMA; İNANÇ, GÜZİDE NEVSUN; ATAGÜNDÜZ, MEHMET PAMİR; ÖZEN ALAHDAB, YEŞİM; DİRESKENELİ, RAFİ HANER; ATUĞ, ÖZLEN; Ergenç İ., KANİ H. T., KARABACAK M., CÖMERT ÖZER E., Mehdiyev S., Jafarov F., ABACAR K. Y., KUTLUĞ AĞAÇKIRAN S., SEVİK G., Aslan R., et al.